VEGFA and glioblastoma: The addition of temozolomide (TMZ) has resulted in a statistically significant increase in median overall survival among those with methylgaunine methyl transferase (MGMT) promoter hypermethylation (~45% of cases) out to ~21 months.3 Beyond its ability to infiltrate brain, GBM also is one of the most highly vascularized human cancers, which led to the development of VEGF inhibitors as an anti-angiogenesis therapy.